Certara (NASDAQ:CERT) Price Target Raised to $12.00

Certara (NASDAQ:CERT) had its target price upped by KeyCorp from $9.00 to $12.00 in a report released on Friday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other equities analysts have also weighed in on the stock. TD Cowen boosted their price target on shares of Certara from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Weiss Ratings cut shares of Certara from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, October 8th. Barclays increased their price objective on shares of Certara from $7.50 to $9.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Finally, UBS Group reiterated a “neutral” rating and issued a $10.00 price objective on shares of Certara in a report on Wednesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $9.18.

Certara Stock Performance

Shares of CERT stock opened at $9.37 on Friday. The stock’s fifty day moving average is $8.54 and its two-hundred day moving average is $6.98. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.55 and a current ratio of 2.55. The firm has a market capitalization of $1.43 billion, a P/E ratio of -20.82 and a beta of 1.42. Certara has a fifty-two week low of $4.45 and a fifty-two week high of $12.94.

Certara (NASDAQ:CERT) last announced its earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%. The business had revenue of $93.27 million for the quarter, compared to analyst estimates of $98.09 million. During the same period last year, the firm earned $0.07 EPS. The company’s revenue for the quarter was down 10.8% compared to the same quarter last year. Research analysts expect that Certara will post 0.22 earnings per share for the current fiscal year.

Institutional Trading of Certara

Several large investors have recently added to or reduced their stakes in the stock. Central Pacific Bank Trust Division raised its holdings in shares of Certara by 8.7% during the 2nd quarter. Central Pacific Bank Trust Division now owns 19,460 shares of the company’s stock worth $127,000 after acquiring an additional 1,558 shares during the period. GAMMA Investing LLC boosted its position in shares of Certara by 21.2% during the 3rd quarter. GAMMA Investing LLC now owns 9,778 shares of the company’s stock valued at $90,000 after acquiring an additional 1,710 shares during the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of Certara by 12.0% in the second quarter. Sequoia Financial Advisors LLC now owns 17,906 shares of the company’s stock valued at $117,000 after purchasing an additional 1,923 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Certara by 12.1% in the first quarter. The Manufacturers Life Insurance Company now owns 23,289 shares of the company’s stock valued at $133,000 after purchasing an additional 2,513 shares during the period. Finally, Pacer Advisors Inc. grew its holdings in shares of Certara by 28.1% in the first quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock valued at $75,000 after purchasing an additional 2,871 shares during the period. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc (NASDAQ:CERT) provides software and technology-enabled services for the biopharmaceutical industry. The company helps drug developers use regulatory science, data analysis, and modeling and simulation to support decisions throughout the research, development, and commercialization lifecycle.

Its offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial design, patient and disease modeling, regulatory submissions, and real-world data analysis.